ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0383

Hidden Risk in Low Frailty: Impact of Elixhauser Comorbidities on In-Hospital Mortality Among Osteoporosis Patients — A Nationwide Analysis

Simran Bhimani1, Anand Reddy Maligireddy2, Sameer Bhimani3, Birju Bhatt4 and Nevena Barjaktarovic5, 1The Wright Center for graduate medical education, Scranton, PA, 2The Wright Center GME, Scarnton, PA, 3The Wright Center for GME, scranton, PA, 4Solara Health NJ, New Jersey, NJ, 5The Wright Center, GME, Scranton, PA

Meeting: ACR Convergence 2025

Keywords: osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0357–0386) Patient Outcomes, Preferences, & Attitudes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Osteoporosis is a common condition associated with increased morbidity, particularly in older adults. While frailty is a known predictor of adverse outcomes, the independent impact of comorbidities in patients with low frailty is not well defined. This study evaluated the association between the Elixhauser Comorbidity Index and in-hospital mortality among hospitalized osteoporosis patients with low frailty and examined differences in hospital utilization and demographics.

Methods: We conducted a retrospective, survey-weighted analysis using the Nationwide Readmissions Database (2016–2022) to identify hospitalized adult ( >18 years) patients with osteoporosis and low frailty scores (≤5). A total of 1,378,142 patients met inclusion criteria and were categorized by the Elixhauser Comorbidity Index: < 3 vs. ≥3. Multivariable logistic regression, adjusted for sex and weekend admission, was used to evaluate the association between comorbidity burden and in-hospital mortality.

Results: Of the 1,378,142 patients included, 775,034 (56.2%) had a high Elixhauser Comorbidity Index (≥3), of whom 88.0% were female. Table 1 outlines the distribution of individual Elixhauser comorbidities across both groups. In-hospital mortality was significantly higher in the high comorbidity group (0.71% vs. 0.23%; p< 0.001). In adjusted analysis, a higher Elixhauser Comorbidity Index was significantly associated with increased odds of in-hospital death (aOR 1.31; 95% CI: 1.29–1.33; p< 0.001). Patients with greater comorbidity burden had longer hospital stays (3.8 vs. 3.1 days; p< 0.001) and higher mean hospital charges ($61,938 vs. $59,837; p< 0.001) Figure 1.

Conclusion: Among hospitalized osteoporosis patients with low frailty, a higher Elixhauser Comorbidity Index independently predicts greater in-hospital mortality, longer length of stay, and increased hospital costs. These findings emphasize the importance of comorbidity assessment for risk stratification and care planning, even in patients considered low-risk by frailty measures.

Supporting image 1

Supporting image 2


Disclosures: S. Bhimani: None; A. Maligireddy: None; S. Bhimani: None; B. Bhatt: None; N. Barjaktarovic: None.

To cite this abstract in AMA style:

Bhimani S, Maligireddy A, Bhimani S, Bhatt B, Barjaktarovic N. Hidden Risk in Low Frailty: Impact of Elixhauser Comorbidities on In-Hospital Mortality Among Osteoporosis Patients — A Nationwide Analysis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/hidden-risk-in-low-frailty-impact-of-elixhauser-comorbidities-on-in-hospital-mortality-among-osteoporosis-patients-a-nationwide-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hidden-risk-in-low-frailty-impact-of-elixhauser-comorbidities-on-in-hospital-mortality-among-osteoporosis-patients-a-nationwide-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology